Amphastar Pharmaceuticals, Inc.
AMPH · Nasdaq · United States
Share price · AMPH
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AMPH's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Sep 2026+4.8%
Nothing announced by AMPH that day or the session before.
- 24 Sep 2026+5.2%
Nothing announced by AMPH that day or the session before.
- 8 May 2026-20.9%
- 27 Feb 2026-23.6%
- 26 Feb 2026-5.3%
- 23 Feb 2026-3.4%
Nothing announced by AMPH that day or the session before.
- 2 Feb 2026+5.4%
Nothing announced by AMPH that day or the session before.
- 15 Jan 2026-6.3%
Nothing announced by AMPH that day or the session before.
- 14 Jan 2026-4.0%
Nothing announced by AMPH that day or the session before.
- 12 Jan 2026+6.0%
Share of unusual movement by asset
For each asset, the share of AMPH's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 45% |
| Sessions with no dated event | — | 55% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Beta-2 adrenergic receptorSmall molecule | Asthma | |
| Approved | Beta-2 adrenergic receptorSmall molecule | Asthma | |
Nasal Glucagon(Baqsimi) | Approved | Glucagon receptor (agonist)Peptide | Diabetes / Hypoglycemia Severe Hypoglycemia |
| Approved | Adrenergic receptor (non-selective, alpha+beta) · Alpha-1 and beta-1/beta-2 adrenergic receptors · Adrenergic receptors, nonselectiveSmall molecule | Asthma |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $208M | $20M | $205M+ $26M short-term inv. | —$43M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $184M | $22M | $224M+ $67M short-term inv. | —$51M operating cash flow | report ↗ |
| 2026-Q1 | $171M | $27M | $171M+ $121M short-term inv. | —$48M operating cash flow | report ↗ |
| 2025-Q3 | $192M | $22M | $217M+ $60M short-term inv. | —$53M operating cash flow | report ↗ |
| 2025-Q2 | $174M | $20M | $188M+ $44M short-term inv. | —$36M operating cash flow | report ↗ |
| 2025-Q1 | $171M | $20M | $183M+ $54M short-term inv. | —$35M operating cash flow | report ↗ |
| 2024-Q3 | $191M | $21M | $192M+ $58M short-term inv. | —$60M operating cash flow | report ↗ |
| 2024-Q2 | $182M | $18M | $190M+ $28M short-term inv. | —$69M operating cash flow | report ↗ |
| 2024-Q1 | $172M | $17M | $201M+ $88M short-term inv. | —$55M operating cash flow | report ↗ |
| 2023-Q3 | $181M | $17M | $271M+ $33M short-term inv. | —$64M operating cash flow | report ↗ |
| 2023-Q2 | $146M | $17M | $151M+ $15M short-term inv. | —$55M operating cash flow | report ↗ |
| 2023-Q1 | $140M | $20M | $177M+ $16M short-term inv. | —$40M operating cash flow | report ↗ |
| 2022-Q3 | $120M | $19M | $157M+ $27M short-term inv. | —$20M operating cash flow | report ↗ |
| 2022-Q2 | $123M | $23M | $166M+ $17M short-term inv. | —$2.8M operating cash flow | report ↗ |
| 2022-Q1 | $120M | $16M | $173M+ $14M short-term inv. | —$51M operating cash flow | report ↗ |
| 2021-Q3 | $112M | $11M | $107M+ $8.0M short-term inv. | —$2.6M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $720M | $86M | $170M+ $113M short-term inv. | —$156M operating cash flow | report ↗ |
Amphastar Pharmaceuticals reported full-year 2025 revenue of $719.89M, down 1.7% YoY, with R&D spend of $85.84M, up 16.1% YoY, and cash and equivalents of $170.41M. GAAP net income was $98.09M, and operating cash flow for the year was $156.1M.
Management emphasized BAQSIMI's sustained double-digit growth as a top revenue driver and noted FDA approvals of its iron sucrose and teriparatide injections. The pipeline includes one ANDA and one biosimilar insulin candidate filed with the FDA, two biosimilar and two generic products in development, and four recently in-licensed proprietary products spanning oncology, ophthalmology, and immunology, including a fully synthetic corticotropin compound. A legal settlement contributed $23.1M to higher general and administrative expenses, and a $6.0M upfront payment supported a licensing agreement with Nanjing Anji Biotechnology.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $732M | $74M | $152M+ $70M short-term inv. | —$213M operating cash flow | report ↗ |
| 2023-FY | $644M | $74M | $145M+ $113M short-term inv. | —$184M operating cash flow | report ↗ |
| 2022-FY | $499M | $75M | $156M+ $20M short-term inv. | —$89M operating cash flow | report ↗ |
| 2021-FY | $438M | $61M | $127M+ $10M short-term inv. | —$98M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 12 sales ($2.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | PETERS WILLIAM J · director, CFO, EVP & TREASURER | Option exercise | 11,000 | $17.99 | $198K | Form 4 |
| 2026-11-16 | PETERS WILLIAM J · director, CFO, EVP & TREASURER | Open-market sale | 11,000 | $29.99 | $330K | Form 4 |
| 2026-11-16 | PETERS WILLIAM J · director, CFO, EVP & TREASURER | Option exercise (derivative) | 11,000 | — | — | Form 4 |
| 2026-11-05 | PETERS WILLIAM J · director, CFO, EVP & TREASURER | Option exercise | 11,000 | $17.99 | $198K | Form 4 |
| 2026-11-05 | PETERS WILLIAM J · director, CFO, EVP & TREASURER | Open-market sale | 12,631 | $28.99 | $366K | Form 4 |
| 2026-11-05 | PETERS WILLIAM J · director, CFO, EVP & TREASURER | Option exercise (derivative) | 11,000 | — | — | Form 4 |
| 2026-11-04 | PETERS WILLIAM J · director, CFO, EVP & TREASURER | Option exercise | 16,000 | $13.03 | $208K | Form 4 |
| 2026-11-04 | PETERS WILLIAM J · director, CFO, EVP & TREASURER | Open-market sale | 16,000 | $28.03 | $448K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 212 reporting institutions held 32.0M shares ($605.9M).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 5,421,343 | $106.2M |
| 2 | DIMENSIONAL FUND ADVISORS LP | 2,027,947 | $39.7M |
| 3 | STATE STREET CORP | 1,607,515 | $31.5M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1,543,655 | $30.2M |
| 5 | TD Asset Management Inc | 1,541,044 | $30.2M |
| 6 | FULLER & THALER ASSET MANAGEMENT, INC. | 1,395,139 | $27.3M |
| 7 | MARSHALL WACE, LLP | 1,025,640 | $20.1M |
| 8 | AMERICAN CENTURY COMPANIES INC | 1,017,538 | $19.9M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 976,650 | $19.1M |
| 10 | Boston Trust Walden Corp | 944,789 | $18.5M |
| 11 | Epoch Investment Partners, Inc. | 898,895 | $17.6M |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 787,816 | $15.4M |
| 13 | D. E. Shaw & Co., Inc. | 665,542 | $13.0M |
| 14 | Invesco Ltd. | 604,774 | $11.8M |
| 15 | RENAISSANCE TECHNOLOGIES LLC | 553,900 | $10.9M |